Ardent Health Inc

Análisis de la acción Ardent Health Inc (ARDT)

$10.940

+0.121 (+1.11%)Al cierre

Loading chart…
High
11.270
Open
10.830
VWAP
11.01
Vol
289.10K
Mkt Cap
Low
10.830
Amount
3.18M
EV/EBITDA, TTM
7.80

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.

AI analysis of Ardent Health Inc (ARDT)

hold

Currently, Ardent Health Partners Inc is trading at $10.96, which is below the average analyst price target of $13.67. The forward P/E ratio is 10.70, indicating a potentially attractive valuation. However, the recent earnings report showed a GAAP EPS of $0.12, missing expectations by $0.05, which raises concerns about profitability. The RSI is at 46.56, suggesting the stock is nearing oversold territory, but is not yet a strong buy signal. The main risk is the 1-year change of -13.50%, indicating significant volatility and potential for further declines.

Métricas de valoración

The current forward P/E ratio for Ardent Health Inc (ARDT) is 10.47, compared to its 5-year average forward P/E of 8.42.

Forward P/E

Overvalued
5Y Average P/E
8.42
Current P/E
10.47
Sobrevalorada
10.13
Infravalorada
6.71

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
6.90
Current EV/EBITDA
7.80
Sobrevalorada
8.43
Infravalorada
5.37

Forward P/S

Fair
5Y Average P/S
0.29
Current P/S
0.23
Sobrevalorada
0.37
Infravalorada
0.20

Whales holding ARDT

G

GoldenTree Asset Management LP

+ HoldingARDT

+2.50%

3M Return

Cronología de eventos

2026-08-04 (ET)

16:30:00

Ardent Health Reports Q2 Revenue of $1.62B

16:30:00

Company Confirms FY26 Revenue Outlook of $6.4B to $6.7B

2026-06-03 (ET)

09:40:00

Morgan Stanley Maintains Equal Weight Rating on Ardent Health with $12 Price Target

2026-06-02 (ET)

16:20:00

Ardent Health Appoints Dave Caspers as CEO

2026-05-14 (ET)

08:20:00

Ardent Health Partners with Fujifilm Healthcare to Implement Imaging Solutions

Noticias

ARDT FAQ — answered by Alphio AI

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings. It operates in the Healthcare sector.

Currently, Ardent Health Partners Inc is trading at $10.96, which is below the average analyst price target of $13.67. The forward P/E ratio is 10.70, indicating a potentially attractive valuation. However, the recent earnings report showed a GAAP EPS of $0.12, missing expectations by $0.05, which raises concerns about profitability. The RSI is at 46.56, suggesting the stock is nearing oversold territory, but is not yet a strong buy signal. The main risk is the 1-year change of -13.50%, indicating significant volatility and potential for further declines.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis